1 July 2021
Spin-out of Monument Therapeutics
Cambridge Cognition is pleased to announce the completion of the spin-out of Monument Therapeutics, a drug development company applying digital phenotyping to central nervous system ("CNS") disorders.
28 June 2021
New £2.2 million contract for at-home cognitive testing in a virtual clinical trial
Cambridge Cognition has been selected as the cognitive assessment partner for a large at-home study. The contract is valued at £2.2 million with revenue expected to be recognised by the Company over three years beginning in H2 2021.
11 June 2021
Cambridge Cognition to join the Brain Health Registry as cognitive assessment partner
Cambridge Cognition Holdings is pleased to announce that it will be joining the University of California, San Francisco (UCSF) Brain Health Registry as a cognitive assessment partner. The Brain Health Registry is an online platform designed to speed up the discovery of treatments for Alzheimer's disease, Parkinson's disease, depression, post-traumatic stress disorder, and other brain disorders.
26 April 2021
Cognition and COVID-19: CANTAB Research Grant - Results
The results of the 2021 CANTAB Research Grant are in! This year's award was focussed on the connection between cognition and COVID-19.
8 April 2021
Cambridge Cognition provides cognitive assessments in an at-home clinical trial
Cambridge Cognition has won a contract with a new pharmaceutical client to provide cognitive assessments in an at-home clinical trial. The contract is worth approximately £0.5 million.
30 March 2021
Cambridge Cognition wins cognitive assessment contract for a schizophrenia trial
Cambridge Cognition has won a £1.3 million contract as the cognitive assessment partner for a schizophrenia trial.